BillionToOne, Inc. (BLLN) Stock Analysis & Investment Frameworks
BillionToOne, Inc. (BLLN) stock analysis on Invetso. Review BillionToOne, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
BillionToOne, Inc. Company Overview
- Exchange: NASDAQ Global Select
- Sector: Healthcare
- Industry: Medical - Diagnostics & Research
- Country: US
BillionToOne, Inc. Key Financial Metrics
- Market Cap: $5.19B
- Revenue: $305.11M
- P/E Ratio: 687.65
- ROE: 9.46%
- ROIC: 6.28%
- Dividend Yield: N/A
About BillionToOne, Inc.
BillionToOne, Inc. is a specialized diagnostics company that innovates by precisely quantifying biological data to create advanced molecular diagnostic solutions. Central to their operations is a cutting-edge molecular counting platform, meticulously engineered to identify and measure individual DNA molecules, thereby significantly enhancing the precision of disease detection. Their product portfolio includes: UNITY Complete: A non-invasive prenatal screen that assesses a fetus's risk for aneuploidies, recessive genetic conditions, and fetal antigens, all from a simple maternal blood sample. Northstar Select: A liquid biopsy test designed to pinpoint specific mutations present in tumors, encompassing deletions, insertions, and point mutations. Northstar Response: A diagnostic tool that enables continuous tracking of cancer progression through detailed methylation assessment. Established in 2016, BillionToOne, Inc. conducts its operations from its headquarters located in Menlo Park, California.